Editor-in-Chief & Deputy Editor 2019-2021

 

Editor-in-Chief:

Nicolas LANTHIER

 

Deputy Editor:

Tim VANUYTSEL

 

Sponsors & Partners



Acta Gastroenterologica Belgica is supported by grants from its major sponsors

 

Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma

 

 

 

 

 

 

Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies


 

 

 

 

 

SRBGE

 

Letters



Campylobacter fetus-induced cellulitis in a Crohn’s disease patient under antiTNFalpha maintenance therapy


Price: €10,00

To the Editor: Case presentation A 54-year-old female patient presented to the emergency department with a tender and swollen left leg, subsequent to a fall. Shortly after, she had developed fever with shivering. Her medical history included type 2 diabetes, Crohn’s disease for 40 years, obesity and alcoholic liver cirrhosis. For the Crohn’s disease, she was treated with azathioprine (2,5 mg/kg once daily) and antiTNFalpha therapy (infliximab 5 mg/kg every 4 weeks, based on trough l335evels) for several years. A week before admission she suffered from nausea, vomitus and diarrhea. The patient had no recent history of travelling, nor of eating improperly cooked meat or unpasteurized milk. [Product Details...]



Comment on the history of Acta Gastro-Enterologica Belgica


Price: €10,00

To the Editor I read with interest the article of T. Moreels et al. in the last issue of Acta Gastro-Enterologica Belgica on the history of the Journal (1). [Product Details...]



Is Ustekinumab the best treatment option in patients with Crohn’s disease and coexistent multiple sclerosis?


Price: €10,00

To the Editor, Crohn’s Disease (CD) and Multiple Sclerosis (MS) are chronic diseases associated with an aberrant immune response upon an environmental trigger in genetically susceptible hosts. We present the case of a young patient with known MS diagnosed with new onset CD. Due to his young age, extended disease (Montreal A2L1,4B1) and smoking habits he was considered candidate for immunosuppression therapy but developed acute pancreatitis 2 weeks after azathioprine administration. Subsequently, ustekinumab was initiated. The patient showed clinical and biochemical response within the first 2 months of therapy and achieved mucosal healing (Simple Endoscopic Score for Crohn’s Disease of 0 compared to 6 at baseline) at 12 months of therapy. No clinical episodes of MS or new lesions on MRI have developed 17 months after treatment commencement. [Product Details...]



Results of a screening campaign for hepatitis C viral infection in a Brussels hospital : do we need to go further?


Price: €10,00

To the Editor, We read with attention the letter of Xavier Verhelst in the last issue of Acta Gastro-Enterologica Belgica evaluating the results of a screening campaign in Lendelede (1). Patients undergoing blood examination were offered anti-HCV screening, further HCV RNA evaluation and hepatology consultation if indicated. [Product Details...]


  • «« Start
  • « Prev
  • 1
  • Next »
  • End »»
Results 1 - 4 of 4